Advances in the Therapy of Advanced Ovarian

Dec 20, 2016 - 1Scientific Director, Centre for Human Reproduction, India. 2Consultant Neurologist ..... Bulowski RM, Ozole RF, Markman M (2007) The m...

0 downloads 0 Views 552KB Size

Recommend Documents

Epithelial ovarian cancer (EOC), along with primary peritoneal cancer (PPC), is the .... (stage ≥ IC) epithelial müllerian tumors were enrolled for the study,. 79% of which had .... treated with nab-paclitaxel 100 mg/m2 days 1,8,15 and BV 10 mg/ k

Apr 8, 2013 - (QOL) in patients treated with a combination of the DNA synthesis inhibitor .... sorafenib, axitinib or cetuximab to gemcitabine38–41.

Mar 17, 2014 - Epithelial ovarian cancer (EOC), along with primary peritoneal cancer (PPC), is .... kg of body weight) q21 days for six cycles in women with advanced- ... 175 mg/m2.23 The study participants were women who had with ...... 10. Ferrara

Jul 15, 2010 - The activity of cediranib, an oral VEGF kinase inhibitor, has also been ... investigating the utility of combining cediranib with carboplatin and ...

Ovarian Cancer gets diagnosed in advanced stage in 75% of patient and thus remains one of the most lethal gynecological malignancies. Despite 80% patients being responsive to platinum based chemotherapies to start with most relapse finally. Hence nee

R., Benevolo, M., Cione, A., and Mottolese, M. The contribution of fluorescence in situ hybridization to immunohistochemistry for evalua- tion of Her-2 in breast ...

University of Michigan, Ann Arbor, MI; Sheba Medical Center, Tel Hashomer, Israel; Assaf. Harofeh Medcl Ctr, Zerifin, Israel; Stanford University School of Medicine, ..... LLC), M Gordon (Pinnacle Oncology Hematology), N Haas (University.

considered a prognostic factor in the case of PTC and. FTC, with all patients younger than 45 years being either ... preferential killing of repair-proficient tumor cells.19. Several retrospective studies and a single .... This dose was ultimately re

differences in prognosis. In order to address these issues, we report our experience regarding treatment and prognosis in elderly patients with. FIGO stages ...

and those with established osteoporosis need additional therapy. CONCLUSION Approved .... tion, it must be given cyclically with drug-free intervals every 3 ...

tion, laser, injection of vascular sclerosants and fetoscopic ligation of the cord have ..... Kumar S. Radiofrequency ablation for selective reduction in complex.

Patients with advanced epithelial ovarian cancer (EOC) should be treated with ... tumour angiogenesis, tyrosine kinase inhibitors, review. ... central role played by the key growth factors in the biology .... cediranib at 20 mg/day during chemotherap

Abstract: Limited progress has been made in the treatment of advanced pancreatic cancer. Gemcitabine was established as a standard of care after a randomized phase III study showed an improvement in clinical benefit response and overall survival over

Mar 15, 1997 - Our 10-year experience with cisplatinum- based polychemotherapy in 196 advanced ovarian cancer patients previously untreated with.

Oct 18, 2017 - The amount of charge in millicoulombs, is calculated as ... coulombs (mQ); multiply this figure by frequency (the number of pulses per second) ...

Sep 8, 2016 - Leal YA, Cedillo-Rivera R, Simón JA, Velázquez JR, Flores LL, Torres ... Scaletsky IC, Aranda KR, Garcia GT, Gonçalves ME, Cardoso SR, Iriya.

treatment free interval larger than 24 months [10, 11]. ... ovarian epithelial cancer (EOC) demands new approaches which might ... with bevacizumab as single agent (15 mg/kg every 21 days) were the first to ..... advanced ovarian cancer is being test

1864, of a rapidly progressive neurodegenera- tive disease and the early 1990s, ..... 100 to 150 mg/die gave no significant results. Phase II and III trials at higher ...

Jan 12, 2017 - an overview of the anticancer mechanisms of HDAC inhibitors and the role of HDAC ... among the successful examples of epigenetic therapy. ..... targets HDAC8) or clinical trials (such as ACY-1215, ..... 2011; 105(2):241-251.

Por su parte, los fármacos anticoagu- lantes son indispensables ... naria a medio plazo, se han ensayado fármacos con ac- .... unwanted effects are serious neutropenia (1% of cases, ..... dictable dose-response curve and do not produce anti-.

monoclonal antibody approved for therapeutic use both in adults and in children aged 6–12 years with severe allergic asthma. The coexistence of severe ...

Dec 1, 2008 - areas with a known tumor if there is gross residual disease or positive surgical margins after resection. Breast, endometrial, gastric, pancreatic ...

He concluded that galanthamine has a similar duration of action as physostigmine, but may produce fewer side effects. M. Pomponi (Catholic University, Rome, ...

Dec 28, 2012 - The promise of personalized medicine is rapidly becoming a reality for the treatment of .... the AGO-Ovar/AIO and EBMT. J Clin Oncol 2007 ...